Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: mokelumne river who wrote (1960)	5/22/2016 6:07:13 PM
From: Mirror Image	Read Replies (1) \| Respond to of 2026

Maybe an offering to raise $3M-$5M could wait until the NDA submittal as Apricus likely has enough cash on hand to make it to September 30. Problem with raising just that amount James - is that if for some reason there are obstacles on the road, then Apricus would be forced to raise at possibly even lower prices - since they would need more money and the FDA outcome would be further away. If they only raise $3M-$5M and the FDA asks for something expensive / or it responds negatively, then it's lights out. You are forced to raise at even lower prices. Just my opinion. I think that $10 M is a fair amount. I would say they are going to give 20M shares to get it. Cash raise at .50 or so. That would put the shares outstanding at around 80 Million. I can easily see a $72 M - $80 M Market Cap on Apricus with an FDA approval. Might even get there after a the FDA signals that it has enough information to warrant a review of the NDA and prior to the actual approval. $72M / 80 M shares = $0.90 $80M / 80 M shares = $1.00 Just my opinion.